Abstract: The buckwheat extract comprises a extract of buckwheat which are enriched in D-fagomine and including 3,4-di-epifagomine, a process for their preparation, pharmaceutical or veterinary compositions, dietary supplements or functional foods containing them, their use alone or in combination with saccharide, an iminocyclitol or probiotics, as a blood glucose levels controlling agent reducing the post-prandial glucose levels, as well as the buckwheat extract for use in the prevention and/or coadjuvant treatment of microbiota imbalance, that reduces the adhesion of some potentially harmful microorganism in the microbiota and therefore increasing the resistance to disease.

Abstract: The present invention discloses a chemoenzymatic process for the preparation of an iminocyclitol corresponding to formula (I), (II), (III) or (IV), wherein: R1 and R2 are the same or different, and independently selected from the group consisting of: H, OH, hydroxymethyl, methyl, ethyl, butyl, pentyl, hexyl, octyl, isopropyl, isobutyl, 2-methylbutyl, and benzyl; R3 is selected from the group consisting of: H, hydroxymethyl, hydroxyethyl, ethyl, butyl, pentyl, hexyl, octyl, dodecyl, isobutyl, isopropyl, isopentyl, 2-methylbutyl, benzyl, and phenylethyl; n: 0 or 1; the process comprising: (i) an aldol addition catalyzed by a D-fructose-6-phosphate aldolase enzyme (FSA) and an acceptor aminoaldehyde; and (ii) an intramolecular reductive amination of the addition adduct obtained in step (i) with H2, in the presence of a metallic catalyst, optionally being carried out said step (ii) in the presence of an aldehyde of formula R3—CHO, wherein R3 is as defined above.

Abstract: The present invention discloses a chemoenzymatic process for the preparation of an iminocyclitol corresponding to formula (I), (II), (III) or (IV), wherein: R1 and R2 are the same or different, and independently selected from the group consisting of: H, OH, hydroxymethyl, methyl, ethyl, butyl, pentyl, hexyl, octyl, isopropyl, isobutyl, 2-methylbutyl, and benzyl; R3 is selected from the group consisting of: H, hydroxymethyl, hydroxyethyl, ethyl, butyl, pentyl, hexyl, octyl, dodecyl, isobutyl, isopropyl, isopentyl, 2-methylbutyl, benzyl, and phenylethyl; n: 0 or 1; the process comprising: (i) an aldol addition catalyzed by a D-fructose-6-phosphate aldolase enzyme (FSA) and an acceptor aminoaldehyde; and (ii) an intramolecular reductive amination of the addition adduct obtained in step (i) with H2, in the presence of a metallic catalyst, optionally being carried out said step (ii) in the presence of an aldehyde of formula R3—CHO, wherein R3 is as defined above.

Abstract: This invention refers to new surface-active compounds derived from arginine of the mono and diacylglyceride type according to the general formula (I) designed to act as surface agents with antimicrobial activity. The variations in the activity will depend on the number of fatty chains and their length. The purification of the intermediate and final products is achieved by means of liquid/liquid, liquid/solid extractions, crystallizations, ion-exchange chromatography and reverse-phase HPLC.

Abstract: This invention refers to new surface-active compounds derived from arginine of the mono and diacylglyceride type according to the general formula (I) designed to act as surface agents with antimicrobial activity. The variations in the activity will depend on the number of fatty chains and their length. The purification of the intermediate and final products is achieved by means of liquid/liquid, liquid/solid extractions, crystallizations, ion-exchange chromatography and reverse-phase HPLC.